DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY.
2002 Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE.
2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA
2000 Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
2007 Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino
Optimum chemotherapy regimen for early breast cancer.
2011 DE LAURENTIIS, Michelino
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
2011 Mcgale, P; Correa, C; Taylor, C; Arriagada, R; Clarke, M; Cutter, D; Davies, C; Ewertz, M; Godwin, J; Gray, R; Pierce, L; Whelan, T; Wang, Y; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues.
1996 Panico, L.; D'Antonio, A.; Salvatore, G.; Mazza, E.; Tortora, Giampaolo; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Giordano, T.; Merino, M.; Salomon, D. S.; Gullick, W. J.; Pettinato, Guido; Bianco, A. R.; Ciardiello, F.
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
2006 Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R.
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
2005 Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, Jf; Hoctin Boes, G; Houghton, J; Locker, Gy; Tobias, Js; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
Prognosis of chronic myelomonocytic leukemia.
1996 L., Catalano; S., Improta; DE LAURENTIIS, Michelino; S., Molica; I., Majolino; P., Musto; A., Fragasso; DE PLACIDO, Sabino; Rotoli, Bruno
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
2011 Davies, C; Godwin, J; Gray, R; Clarke, M; Cutter, D; Darby, S; Mcgale, P; Pan, Hc; Taylor, C; Wang, Yc; Dowsett, M; Ingle, J; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996 Carlomagno, Chiara; F., Perrone; C., Gallo; DE LAURENTIIS, Michelino; R., Lauria; A., Morabito; Pettinato, Guido; L., Panico; A., D'Antonio; A. R., Bianco; DE PLACIDO, Sabino
Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer.
2012 Giordano, A; Gao, H; Anfossi, S; Cohen, E; Mego, M; Lee, Bn; Tin, S; DE LAURENTIIS, Michelino; Parker, Ca; Alvarez, Rh; Valero, V; Ueno, Nt; DE PLACIDO, Sabino; Mani, Sa; Esteva, Fj; Cristofanilli, M; Reuben, Jm
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
2007 DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
2002 Di Lorenzo, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, Gaetano; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators.
1994 P. M., Ravdin; DE LAURENTIIS, Michelino; T., Vendely; G. M., Clark
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
2005 Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| SECOND-LINE CHEMOTHERAPY WITH A HYBRID-ALTERNATING REGIMEN OF BOLUS FLUOROURACIL MODULATED BY METHOTREXATE AND INFUSIONAL FLUOROURACIL MODULATED BY FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL CANCERPRETREATED WITH FLUOROURACIL. A PHASE II STUDY. | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Carlomagno, C; DE LAURENTIIS, Michelino; Lauria, R; Arpino, Grazia; Massarelli, E; Ferrara, C; Milano, A; VERNAGLIA LOMBARDI, A; Costanzo, R; Catalano, G; Bianco, Ar; DE PLACIDO, Sabino | |
| IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino | |
| NUCLEAR DNA CONTENT-DERIVED PARAMETERS CORRELATED WITH HETEROGENEOUS EXPRESSION PF P53 AND BCL-2 PROTEINS IN CLEAR CELL RENAL CARCINOMA | 1.1 Articolo in rivista | 2000 | Pepe, S; Ruggiero, A; D'Acquisto, M; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. | 1.1 Articolo in rivista | 2005 | DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. | 1.1 Articolo in rivista | 2007 | Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino | |
| Optimum chemotherapy regimen for early breast cancer. | 1.1 Articolo in rivista | 2011 | DE LAURENTIIS, Michelino | |
| Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. | 1.1 Articolo in rivista | 2011 | Mcgale, P; Correa, C; Taylor, C; Arriagada, R; Clarke, M; Cutter, D; Davies, C; Ewertz, M; Godwin, J; Gray, R; Pierce, L; Whelan, T; Wang, Y; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara | |
| Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues. | 1.1 Articolo in rivista | 1996 | Panico, L.; D'Antonio, A.; Salvatore, G.; Mazza, E.; Tortora, Giampaolo; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Giordano, T.; Merino, M.; Salomon, D. S.; Gullick, W. J.; Pettinato, Guido; Bianco, A. R.; Ciardiello, F. | |
| Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. | 1.1 Articolo in rivista | 2006 | Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R. | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | 1.1 Articolo in rivista | 2005 | Howell, A; Cuzick, J; Baum, M; Buzdar, A; Dowsett, M; Forbes, Jf; Hoctin Boes, G; Houghton, J; Locker, Gy; Tobias, Js; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara | |
| Prognosis of chronic myelomonocytic leukemia. | 1.1 Articolo in rivista | 1996 | L., Catalano; S., Improta; DE LAURENTIIS, Michelino; S., Molica; I., Majolino; P., Musto; A., Fragasso; DE PLACIDO, Sabino; Rotoli, Bruno | |
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. | 1.1 Articolo in rivista | 2011 | Davies, C; Godwin, J; Gray, R; Clarke, M; Cutter, D; Darby, S; Mcgale, P; Pan, Hc; Taylor, C; Wang, Yc; Dowsett, M; Ingle, J; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. | 1.1 Articolo in rivista | 1996 | Carlomagno, Chiara; F., Perrone; C., Gallo; DE LAURENTIIS, Michelino; R., Lauria; A., Morabito; Pettinato, Guido; L., Panico; A., D'Antonio; A. R., Bianco; DE PLACIDO, Sabino | |
| Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. | 1.1 Articolo in rivista | 2012 | Giordano, A; Gao, H; Anfossi, S; Cohen, E; Mego, M; Lee, Bn; Tin, S; DE LAURENTIIS, Michelino; Parker, Ca; Alvarez, Rh; Valero, V; Ueno, Nt; DE PLACIDO, Sabino; Mani, Sa; Esteva, Fj; Cristofanilli, M; Reuben, Jm | |
| Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. | 1.1 Articolo in rivista | 2007 | DI LORENZO, G; Autorino, R; Perdona, S; DE LAURENTIIS, Michelino; D'Armiento, FRANCESCO PAOLO; Cancello, G; Mirone, Vincenzo; Imbimbo, Ciro; Longo, Nicola; Altieri, Vincenzo; Tortora, Giampaolo; Figg, Wd; DE PLACIDO, Sabino | |
| Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. | 1.1 Articolo in rivista | 2002 | Di Lorenzo, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, Gaetano; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
| Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. | 1.1 Articolo in rivista | 1994 | P. M., Ravdin; DE LAURENTIIS, Michelino; T., Vendely; G. M., Clark | |
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. | 1.1 Articolo in rivista | 2005 | Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino |